Pediatric vasculitis

Current Opinion in Rheumatology

Volumn 28, Issue 1, 2016, Pages 29-38

  Barut, Kenan ^a   Sahin, Sezgin ^a   Kasapcopur, Ozgur ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antineutrophilic cytoplasmic antibody associated vasculitis; Henoch Schonlein purpura IgA vasculitis; Kawasaki disease; Pediatric vasculitis; Takayasu's arteritis

Indexed keywords

ACUTE PHASE PROTEIN; ADENOSINE DEAMINASE; ADENOSINE DEAMINASE 2; GLUCOCORTICOID; IMMUNOGLOBULIN A; UNCLASSIFIED DRUG;

ADENOSINE DEAMINASE DEFICIENCY; ANAPHYLACTOID PURPURA; AORTA ARCH SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD DISEASE; CLINICAL FEATURE; DISEASE CLASSIFICATION; EOSINOPHILIC GRANULOMA; FATIGUE; FEVER; HUMAN; INCIDENCE; MALAISE; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTICENTER STUDY (TOPIC); PATHOGENESIS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VASCULITIS; ANCA ASSOCIATED VASCULITIS; BRAIN VASCULITIS; CHILD; CLASSIFICATION;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CHILD; HUMANS; MUCOCUTANEOUS LYMPH NODE SYNDROME; POLYARTERITIS NODOSA; PURPURA, SCHOENLEIN-HENOCH; TAKAYASU ARTERITIS; VASCULITIS; VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 84948719899     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000236     Document Type: Review

References (53)

1. Eleftheriou D, Batu ED, Ozen S, Brogan PA. Vasculitis in children. Nephrol Dial Transplant 2015; 30:i94-i103.
2. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013; 65:1-11.
3. Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schö nlein purpura, childhood polyarteritis nodosa, childhood We-gener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010; 69:798-806.
4. Baldwin C, Carette S, Pagnoux C. Linking classification and therapeutic management of vasculitides. Arth Res Therap 2015; 17:138.
5. Mahr A, de Menthon M. Classification and classification criteria for vasculitis: achievements, limitations and prospects. Curr Opin Rheumatol 2015; 27:1-9.
6. Batu ED, Ozen S. Vasculitis: do we know more to classify better? Pediatr Nephrol 2015; 30:1425-1430.
7. Greco A, De Virgilio A, Rizzo M. Kawasaki disease: an evolving paradigm. Autoimmun Rev 2015; 14:703-709.
8. Twilt M, Benseler SM. Childhood inflammatory brain diseases: patho-genesis, diagnosis and therapy. Rheumatology (Oxford) 2014; 53:1359-1368.
9. Pohl M. Henoch-Schönlein purpura nephritis. Pediatr Nephrol 2015; 30:245-252.
10. An J, Lü Q, Zhao H, et al. A study on the association between C1GALT1 polymorphisms and the risk of Henoch-Schonlein purpura in a Chinese population. Rheumatol Int 2013; 33:2539-2542.
11. Ercan G, Kasapçopur O, Akdenizli E, Arisoy N. The role of streptococcal infection in Henoch-Schönlein purpura. J Trop Pediatr 2004; 50:187-188.
12. Rigante D, Castellazzi L, Bosco A, Esposito S. Is there a crossroad between infections, genetics, and Henoch-Schönlein purpura? Autoimmun Rev 2013; 12:1016-1021.
13. Yu HH, Liu PH, Yang YH,et al. Chemokine MCP1/CCL2 and RANTES/CCL5 gene polymorphisms influence Henoch-Schonlein purpura susceptibility and severity. J Formos Med Assoc 2015; 114:347-352.
14. Trnka P. Henoch-Schönlein purpura in children. J Paediatr Child Health 2013; 49:995-1003.
15. Berube MD, Blais N, Lanthier S. Neurologic manifestations of Henoch-Schönlein purpura. Handb Clin Neurol 2014; 120:1101-1111.
16. Chen T, Lu YH, Wang WJ, et al. Elevated urinary levels of cystatin C and neutrophil gelatinase-associated lipocalin in Henoch-Schönlein purpura patients with renal involvement. PLoS One 2014; 9:e101026.
17. Weiss PF, Feinstein JA, Luan X, et al. Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. Pediatrics 2007; 120:1079-1087.
18. Cohen N, Mimouni FB, Friedel N, Amarilyo G. Predictors of hospital length of stay in pediatric Henoch-Schonlein purpura. Rheumatol Int 2015; 35:1561-1564; Mar 25. [Epub ahead of print]
19. Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J Epidemiol 2012; 22:216-221.
20. Burns JC, Herzog L, Fabri O, et al. Seasonality of Kawasaki disease: a global perspective. PLoS One 2013; 8:e74529.
21. Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis Child 2015; 25:307536. [Epub ahead of print]
22. Mortazavi SH, Amin R, Alyasin S, et al. Down-regulation of TLR2, 3, 9 and signaling mediators, MyD88 and TRIF, gene transcript levels in patients with Kawasaki disease treated with IVIG. Iran J Allergy Asthma Immunol 2015; 14:188-197.
23. Yoon KL. Update of genetic susceptibility in patients with Kawasaki disease. Korean J Pediatr 2015; 58:84-88.
24. Rezai MS, Shahmohammadi S. Erythema at BCG inoculation site in Kawasaki disease patients. Mater Sociomed 2014; 26:256-260.
25. Bayers S, Shulman ST, Paller AS. Kawasaki disease: part I. Diagnosis, clinical features,and pathogenesis. J Am Acad Dermatol 2013; 69:501; e1-e11.
26. Giacchi V, Sciacca P, Stella I, et al. Assessment of coronary artery intimal thickening in patients with a previous diagnosis of Kawasaki disease by using high resolution transthoracic echocardiography: our experience. BMC Car-diovasc Disord 2014; 14:106.
27. Yeom JS, Woo HO, Park JS, et al. Kawasaki disease in infants. Korean J Pediatr 2013; 56:377-382.
28. Kumar S, Vaidyanathan B, Gayathri S, Rajam L. Systemic onset juvenile idiopathic arthritis with macrophage activation syndrome misdiagnosed as Kawasaki disease: case report and literature review. Rheumatol Int 2013; 33:1065-1069.
29. Takahara T, Shimizu M, Nakagishi Y, et al. Serum IL-18 as a potential specific marker for differentiating systemic juvenile idiopathic arthritis from incomplete Kawasaki disease. Rheumatol Int 2015; 35: 81-84.
30. Bayers S, Shulman ST, Paller AS. Kawasaki disease:part II. Complications and treatment. J Am Acad Dermatol 2013; 69:513; e1-8.
31. Goel R, Kumar TS, Danda D, et al. Childhood onset Takayasu arteritis experience from a tertiary care center in South India. J Rheumatol 2014; 41:1183-1189.
32. Szugye HS, Zeft AS, Spalding SJ. Takayasu arteritis in the pediatric population: a contemporary United States-Based Single Center Cohort. Pediatr Rheumatol Online J 2014; 12:21.
33. MendiolaRamírez K, Portillo Rivera AC, Galicia Reyes A, et al. Type III Takayasu's arteritis in a pediatric patient. Case report and review of the literature. Reumatol Clin 2012; 8:216-219.
34. Eleftheriou D, Varnier G, Dolezalova P, et al. Takayasu arteritis in childhood: retrospective experience from a tertiary referral centre in the United Kingdom. Arthritis Res Ther 2015; 17:36.
35. Watson L, Brogan P, Peart I, et al. Diagnosis and assessment of disease activity in Takayasu arteritis: a childhood case illustrating the challenge. Case Rep Rheumatol 2014; 2014:603171.
36. Misra R, Danda D, Rajappa SM, et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford) 2013; 52:1795-1801.
37. Tombetti E, Di Chio M, Sartorelli S, et al. Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis. Arthritis Res Ther 2014; 16:479.
38. Keser G, Direskeneli H, Aksu K. Management of Takayasu arteritis: a systematic review. Rheumatology (Oxford) 2014; 53:793-801.
39. Bravo Mancheno B, Perin F, Guez Vázquez Del Rey Mdel M, et al. Successful tocilizumab treatment in a child with refractory Takayasu arteritis. Pediatrics 2012; 130:e1720-e1724.
40. Iudici M, Puechal X, Pagnoux C, et al. Brief report: childhood-onset systemic necrotizing vasculitides: long-term data from the French vasculitis study group registry. Arthritis Rheumatol 2015; 67:1959-1965.
41. Eleftheriou D, Dillon MJ, Tullus K, et al. Systemic polyarteritis nodosa in the young: a single-center experience over thirty-two years. Arthritis Rheum 2013; 65:2476-2485.
42. Merlin E, Mouy R, Pereira B, et al. Long-term outcome of children with pediatric-onset cutaneous and visceral polyarteritis nodosa. Joint Bone Spine 2015; 82:251-257.
43. Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014; 370:921-931.
44. Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014; 370:911-920.
45. Garg N, Kasapcopur O, Foster J 2nd, et al. Novel adenosinede aminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr 2014; 173:827-830.
46. Gonzalez-Santiago TM, Zavialov A, Saarela J, et al. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatol 2015; 1. [Epub ahead of print]
47. Twilt M, Benseler S, Cabral D. Granulomatosis with polyangiitis in childhood. Curr Rheumatol Rep 2012; 14:107-115.
48. Cabral DA, Uribe AG, Benseler S, et al. Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. Arthritis Rheum 2009; 60:3413-3424.
49. Bohm M, Gonzalez Fernandez MI, Ozen S, et al. Clinical features of childhood granulomatosis with polyangiitis (Wegener's granulomatosis). Pediatr Rheumatol Online J 2014; 12:18.
50. Morishita K, Li SC, Muscal E, et al. Assessing the performance of the Birmingham Vasculitis Activity Score at diagnosis for children with antineu-trophilcytoplasmic antibody-associated vasculitis in A Registry for Childhood Vasculitis (ARChiVe). J Rheumatol 2012; 39:1088-1094.
51. Dolezalova P, Price-Kuehne FE, Ozen S, et al. Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis 2013; 72:1628-1633.
52. Morishita K, Brown K, Cabral D. Pediatric vasculitis: advances in treatment. Curr Opin Rheumatol 2015; 27:493-499.
53. Cellucci T, Tyrrell PN, Pullenayegum E, Benseler SM. Von Willebrand factor antigen: a possible biomarker of disease activity in childhood central nervous system vasculitis? Rheumatology (Oxford) 2012; 51:1838-1845.